The central argument of the review is that resistance in pancreatic cancer is not attributable to any single molecular alteration. Instead, the authors describe an interconnected web of mechanisms that includes intrinsic resistance present from the outset of treatment, adaptive resistance induced by the therapy itself, and acquired resistance that emerges through genomic evolution and clonal selection. Under the selective pressure of chemotherapy or targeted agents, subpopulations of tumor cells carrying survival advantages expand and dominate, reshaping the tumor’s molecular landscape. This evolutionary view is consistent with decades of evidence that pancreatic tumors harbor extraordinary genetic heterogeneity, with distinct clones coexisting within the same lesion and responding differently to the same drug. The practical consequence is sobering: a treatment regimen informed by a single baseline biopsy may be accurate on day one and obsolete weeks later.

Among the mechanisms the review highlights, cancer stemness and phenotypic plasticity occupy a particularly important place. Pancreatic tumors contain subpopulations of cells with stem-like properties that are intrinsically more resistant to chemotherapy and radiation, capable of self-renewal, and implicated in relapse after treatment. Beyond stemness, plasticity allows tumor cells to switch between classical and basal-like molecular subtypes, to transition between epithelial and mesenchymal states, and to rewire their signaling networks in response to therapeutic pressure. Studies cited in the review demonstrate that such state transitions can occur rapidly and reversibly, meaning that a tumor’s phenotype at biopsy may not reflect its phenotype under treatment. This fluidity undermines the premise of one-time molecular profiling and provides a biological rationale for repeated assessment throughout the course of therapy.

Metabolic adaptation represents another pillar of resistance described in detail. Pancreatic cancer cells reprogram their metabolism to survive nutrient-poor, hypoxic tumor environments and to withstand cytotoxic stress, shifting between glycolytic and oxidative pathways, scavenging extracellular nutrients, and altering their dependence on key metabolic enzymes. These adaptations are not merely passive consequences of the tumor microenvironment; they are active survival strategies that can be selected for by treatment. The review also emphasizes the contribution of the tumor microenvironment itself, noting that the dense desmoplastic stroma characteristic of pancreatic cancer creates physical barriers to drug delivery, secretes immunosuppressive factors, and supports cancer-associated fibroblasts and immune cells that actively shield tumor cells from both chemotherapy and immunotherapy. Stromal interactions, the authors note, can induce or amplify nearly every other resistance mechanism they catalog.

Against this backdrop of biological complexity, the review surveys emerging therapeutic approaches that target specific resistance mechanisms. Perhaps the most consequential recent development is the arrival of KRAS inhibitors. Activating mutations in KRAS, most commonly KRAS G12D and the historically dominant KRAS G12C, drive the majority of pancreatic cancers, and after decades in which KRAS was considered undruggable, allele-specific inhibitors have now entered clinical use and clinical trials. Yet the review is candid about the limits of this progress: resistance to KRAS inhibition emerges through multiple routes, including reactivation of downstream pathways, bypass signaling, and epithelial-to-mesenchymal transitions. Combination strategies, such as vertical pathway inhibition that blocks KRAS signaling at multiple nodes simultaneously, are presented as one promising route to delay or overcome adaptive resistance.

The authors also summarize strategies aimed at the tumor microenvironment and immune system, including stroma-targeting agents, immunotherapeutic approaches, and personalized mRNA neoantigen vaccines that have shown the ability to stimulate T cell responses in pancreatic cancer patients. Additional therapeutic axes include agents targeting metabolic dependencies, such as autophagy inhibitors combined with MAPK pathway inhibitors in early-phase trials, and approaches exploiting defects in DNA damage repair pathways, which sensitize some tumors to platinum chemotherapy and PARP inhibitors. However, the review repeatedly stresses that durable efficacy remains limited by biological heterogeneity and by the tumors’ capacity to adapt, reinforcing the authors’ central claim that no single-agent or single-mechanism strategy is likely to be sufficient on its own.

The most distinctive contribution of the review is its proposal of a Dynamic Precision Oncology framework, abbreviated DPO, which extends conventional precision oncology beyond its dependence on baseline molecular profiling. Under DPO, tumor assessment would become longitudinal and iterative, integrating repeated measurements of tumor genomics, circulating tumor DNA, the serum biomarker CA19-9, imaging and radiomic features, and clinical characteristics collected over the entire course of treatment. The framework emphasizes three recurring steps: the ongoing detection and characterization of emerging resistance, the adaptation of treatment based on the specific mechanism identified, and subsequent reassessment to determine whether the adaptation succeeded. Critically, the authors specify that treatment modification should follow mechanistic evidence rather than occurring automatically in response to a single biomarker change, distinguishing DPO from simplistic reflexive switching.

The technological foundations for such a framework are, the review argues, increasingly in place. Liquid biopsy studies have shown that circulating tumor DNA dynamics can reveal disease progression earlier than radiological imaging in advanced pancreatic cancer, and ctDNA kinetics have been incorporated into emerging response criteria such as ctDNA-RECIST. Comprehensive genomic profiling is already feasible in routine clinical settings, and radiomics offers the prospect of extracting quantitative, treatment-relevant information from standard imaging without additional procedures. Artificial intelligence and machine learning, the authors suggest, will be essential for integrating these heterogeneous data streams into actionable treatment recommendations. Real-world studies demonstrating the clinical utility of genomic profiling in advanced pancreatic cancer lend practical support to the feasibility of repeated molecular assessment, though the review acknowledges that cost, turnaround time, and assay sensitivity remain barriers.

The authors are careful to frame DPO as a conceptual framework rather than a validated clinical protocol. They explicitly state that prospective studies are needed to validate the relevant biomarkers, define actionable thresholds for intervention, and determine whether longitudinal, resistance-guided strategies actually improve clinical outcomes in pancreatic ductal adenocarcinoma. This candor distinguishes the review from more promotional visions of personalized medicine and reflects the hard-won lessons of a disease in which many promising approaches have faltered in clinical trials. Nevertheless, the review’s message is ultimately one of cautious optimism: by treating therapeutic resistance as an evolutionary process to be monitored and countered continuously, rather than a fixed property to be predicted once, oncology may finally acquire the tempo needed to keep pace with one of medicine’s most adaptable cancers. For a disease with five-year survival rates that remain in the single digits, that shift in perspective, from static snapshots to dynamic surveillance, may prove to be the conceptual breakthrough that translates a decade of mechanistic discovery into longer, better lives for patients.

Subject of Research: Therapeutic resistance mechanisms and dynamic precision oncology in pancreatic ductal adenocarcinoma

Article Title: Overcoming cancer resistance in pancreatic cancer: toward dynamic precision oncology

Article References: Okabayashi, T., Tabuchi, M., Tokumaru, T., Uemura, S., & Tamura, S. (2026). Overcoming cancer resistance in pancreatic cancer: toward dynamic precision oncology. Molecular Biology Reports, 53(1), Article 1570. https://doi.org/10.1007/s11033-026-12767-x

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12767-x

Keywords: pancreatic cancer, pancreatic ductal adenocarcinoma, therapeutic resistance, dynamic precision oncology, KRAS inhibitors, circulating tumor DNA, liquid biopsy, tumor microenvironment, cancer stem cells, phenotypic plasticity, tumor evolution, precision oncology

KRAS mutations are notorious drivers in approximately 30% of all human cancers, with an overwhelming 90% incidence in pancreatic ductal adenocarcinoma (PDAC), a malignancy characterized by dismal prognosis and limited treatment options. KRAS inhibitors have been hailed as potential game-changers, yet their clinical efficacy is frequently undermined by acquired drug resistance. This research addresses a critical gap: the role of metabolic rewiring and mitochondrial quality control, particularly mitophagy, in mediating resistance to KRAS-targeted therapies.

The study centers on the observation that KRAS inhibitors, specifically MRTX1133 targeting the KRAS(G12D) mutant and the pan-RAS inhibitor RMC-6236, lead to a significant reduction in ATP citrate lyase (ACLY) expression and consequently decrease cytosolic AcCoA levels in both murine KPC cells and human PDAC AsPC-1 cells harboring KRAS(G12D) mutations. This metabolic suppression initiates a cascade culminating in elevated mitophagy, a selective autophagic process for mitochondrial turnover. Importantly, the induction of mitophagy by KRAS inhibition was effectively antagonized by exogenous acetate supplementation, underscoring the centrality of the ACLY-AcCoA axis in controlling this process.

Delving deeper, the researchers demonstrated that mitophagy triggered by KRASi is strikingly dependent on NLRX1, a mitochondrial NOD-like receptor previously implicated in innate immune signaling and mitochondrial homeostasis. NLRX1-deficient cells exhibited a near-complete abrogation of KRASi-induced mitophagy, illuminating its indispensable role as a mediator of mitochondrial quality control in this context. The absence of NLRX1 not only hindered mitophagy but also resulted in pronounced accumulation of reactive oxygen species (ROS) and heightened cellular oxidative stress, as evidenced by increased NADP⁺/NADPH ratios.

The functional consequences of these molecular events were profound. NLRX1 deficiency sensitized cancer cells to KRAS inhibition, augmenting cytotoxicity in both murine and human KRAS-mutant PDAC and lung cancer models. This finding was further bolstered by experiments involving the antioxidant N-acetyl-L-cysteine (NAC), which rescued the viability of NLRX1-deficient cells exposed to KRASi by mitigating oxidative stress. It became evident that the mitophagy pathway represents a cellular defensive maneuver that mitigates ROS-induced damage to sustain tumor cell survival during KRAS-targeted therapy.

Complementing the in vitro analyses, in vivo studies employing a subcutaneous KPC tumor model in NSG mice cemented the therapeutic relevance of the ACLY–AcCoA–NLRX1 axis. Mice receiving the KRAS inhibitor MRTX1133 exhibited notable tumor regression, an effect amplified in the absence of NLRX1. Moreover, immunoblot and histological analyses revealed that while Acly suppression occurred uniformly across conditions, mitochondrial protein levels—indicative of mitophagy—were preserved in NLRX1-deficient tumors, affirming the disrupted mitophagic response. Consistently, ROS levels were reduced in control tumors following KRASi but escalated in NLRX1-lacking specimens, reinforcing the interplay between mitophagy, redox balance, and therapy resistance.

These revelations shift the paradigm by identifying mitophagy not merely as a housekeeping process but as a vital resistance mechanism exploited by cancer cells under pharmacologic assault. The study’s insights suggest that targeting the metabolic regulation of mitophagy—specifically through the ACLY-AcCoA-NLRX1 signaling axis—may enhance the efficacy of KRAS inhibitors and suppress tumor adaptation.

Intriguingly, this research also reports synergistic antitumor effects when combining KRAS inhibitors with mitophagy inhibitors like Mdivi-1, which exacerbates mitochondrial dysfunction and oxidative stress in cancer cells. This dual targeting strategy presents a compelling therapeutic avenue, potentially circumventing the resilience conferred by mitophagy-mediated mitochondrial clearance.

From a mechanistic viewpoint, the intimate connection between decreased ACLY activity and mitophagy induction underscores the broader concept that metabolic state functions as a signaling nexus. Cytosolic AcCoA emerges as more than a metabolic intermediate; it acts as a signaling metabolite communicating cellular energy and nutrient status to the mitophagy machinery. This axis elegantly illustrates how metabolic rewiring can intersect with organelle quality control to govern cell fate decisions during oncogenic stress.

Beyond immediate therapeutic implications, these findings raise significant questions about mitophagy’s role across diverse KRAS-mutant tumor types and contexts of therapy resistance. As chronic KRAS inhibition becomes more prevalent in clinical oncology, understanding how tumor cells engage mitochondrial quality control pathways could guide the design of combinatorial regimens that preempt or reverse resistance.

Moreover, this study highlights the vital importance of ROS homeostasis in malignancies driven by KRAS mutations. The intricate balance between mitochondrial removal and redox signaling revealed here may represent a universal vulnerability exploitable across cancers characterized by oxidative stress adaptations.

In conclusion, the elucidation of the ACLY–AcCoA–NLRX1 axis as a regulator of mitophagy in KRAS inhibitor-mediated drug resistance broadens the framework of cancer metabolism and organelle dynamics in oncogenesis. It opens exciting pathways for innovative treatments that disrupt tumor adaptive mechanisms, potentially transforming outcomes for patients afflicted with some of the deadliest KRAS-driven cancers.

Subject of Research:
KRAS-mutant cancer metabolism, mitophagy, and drug resistance mechanisms

Article Title:
Cytosolic acetyl-coenzyme A is a signalling metabolite to control mitophagy

Article References:
Zhang, Y., Shen, X., Shen, Y. et al. Cytosolic acetyl-coenzyme A is a signalling metabolite to control mitophagy. Nature (2025). https://doi.org/10.1038/s41586-025-09745-x

Image Credits: AI Generated

DOI:
https://doi.org/10.1038/s41586-025-09745-x